Risk of Vascular Toxicity with Platinum Based Chemotherapy in Elderly Patients with Bladder Cancer

Journal of Urology

Volumn 195, Issue 1, 2016, Pages 33-40

  Gupta, Amit ^a   Long, Jessica B ^b   Chen, Jersey ^c   Gross, Cary P ^b   Feldman, Darren R ^d   Steingart, Richard M ^d  

^a UNIVERSITY OF IOWA   (United States)

^b YALE CANCER CENTER   (United States)

^c KAISER PERMANENTE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

cardiotoxicity; drug therapy; platinum; thromboembolism; urinary bladder neoplasms

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; ANTINEOPLASTIC AGENT;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AGE; AGED; ANGINA PECTORIS; ARTERY EMBOLISM; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; GENDER; HEART FAILURE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TRANSIENT ISCHEMIC ATTACK; VERY ELDERLY; CHEMICALLY INDUCED; RISK; THROMBOEMBOLISM; URINARY BLADDER NEOPLASMS; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; FEMALE; HUMANS; MALE; RISK; THROMBOEMBOLISM; URINARY BLADDER NEOPLASMS; VASCULAR DISEASES;

EID: 84983111441     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.08.088     Document Type: Article

References (20)

1. SEER Stat Fact Sheets: Bladder Cancer. Available at http://seer.cancer.gov/statfacts/html/urinb.html.
2. M.P. Porter, M.C. Kerrigan, B.M. Donato, and et al. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer Urol Oncol 29 2011 252
3. S. Khan, C.L. Chen, M.S. Brady, and et al. Unstable angina associated with cisplatin and carboplatin in a patient with advanced melanoma J Clin Oncol 30 2012 e163
4. E.T. Yeh, and C.L. Bickford Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management J Am Coll Cardiol 53 2009 2231
5. D.R. Feldman, G.J. Bosl, J. Sheinfeld, and et al. Medical treatment of advanced testicular cancer JAMA 299 2008 672
6. R.A. Moore, N. Adel, E. Riedel, and et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis J Clin Oncol 29 2011 3466
7. C.M. Tully, A.B. Apolo, E.C. Zabor, and et al. The high incidence of vascular thromboembolic events (VTE) in advanced urothelial cancer (UC) patients (pts) treated with carboplatin (Cb): analysis of treatment with gemcitabine (G)/cb (GCb), gcb/bevacizumab (GCbBev), or gemcitabine/cisplatin (GCis) J Clin Oncol 32 suppl. 2014 abstract 316
8. A.B. Apolo, A.M. Regazzi, M.I. Milowsky, and et al. Vascular thromboembolic events in patients (pts) with advanced urothelial cancer (UC) treated with carboplatin/gemcitabine alone or in combination with bevacizumab J Clin Oncol 27 suppl. 2009 5074
9. P.M. Czaykowski, M.J. Moore, and I.F. Tannock High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy J Urol 160 1998 2021
10. N.M. Hahn, W.M. Stadler, R.T. Zon, and et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75 J Clin Oncol 29 2011 1525
11. E.R. Plimack, J.H. Hoffman-Censits, A. Kutikov, and et al. Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): final results of a multicenter phase II study J Clin Oncol 32 suppl. 2014 5s abstract 4513
12. Surveillance, Epidemiology, and End Results Program. Available at http://seer.cancer.gov/.
13. J.L. Warren, C.N. Klabunde, D. Schrag, and et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population Med Care 40 2002 IV
14. A. Albini, G. Pennesi, F. Donatelli, and et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention J Natl Cancer Inst 102 2010 14
15. D. Tassinari, S. Sartori, G. Drudi, and et al. Cardiac arrhythmias after cisplatin infusion: three case reports and a review of the literature Ann Oncol 8 1997 1263
16. A.A. Khorana, N.M. Kuderer, E. Culakova, and et al. Development and validation of a predictive model for chemotherapy-associated thrombosis Blood 111 2008 4902
17. M.T. Severinsen, S.R. Kristensen, S.P. Johnsen, and et al. Smoking and venous thromboembolism: a Danish follow-up study J Thromb Haemost 7 2009 1297
18. M.D. Silverstein, J.A. Heit, D.N. Mohr, and et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study Arch Intern Med 158 1998 585
19. S. Barni, R. Labianca, G. Agnelli, and et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study J Transl Med 9 2011 179
20. P. Zareba, L. Patterson, R. Pandya, and et al. Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomy Urol Oncol 32 2014 975